Ipca Labs, BRL to co-develop next-gen biologics for cancer and autoimmune diseases
The collaboration aims to develop differentiated biologics that offer greater convenience and accessibility for patients
The collaboration aims to develop differentiated biologics that offer greater convenience and accessibility for patients
The company has reported total income of Rs. 1607.85 crores during the period ended June 30, 2022.
Subscribe To Our Newsletter & Stay Updated